title: Absence of Neisseria meningitidis serogroup C-specific antibodies during the first year of life in the Netherlands: an age group at risk?
abstract: In The Netherlands, a single meningococcal serogroup C conjugate (MenCC) vaccination is administered to children at the age of 14 months. Here, we report the levels of MenC polysaccharide-specific antibodies in children at birth and at 3, 11, and 12 months of age and the presence of functional antibodies at 11 months of age, before infants receive their MenCC immunization. We observed a rapid decline in polysaccharide-specific antibodies after birth and no induction of naturally elicited polysaccharide-specific antibodies. Furthermore, at 11 months of age, no bactericidal antibodies are observed. These data indicate that these infants may be at risk in the period prior to MenCC immunization, if Neisseria meningitidis serogroup C starts to (re)circulate.
authors.affiliation: Laboratory for Infectious Diseases and Screening, National Institute of Public Health and the Environment, Bilthoven, The Netherlands. Richarda.de.Voer@rivm.nl
authors.forename: Richarda M
authors.initials: RM
authors.lastname: de Voer
authors.forename: Fiona R M
authors.initials: FR
authors.lastname: van der Klis
authors.forename: Laetitia E M
authors.initials: LE
authors.lastname: Niers
authors.forename: Ger T
authors.initials: GT
authors.lastname: Rijkers
authors.forename: Guy A M
authors.initials: GA
authors.lastname: Berbers
mesh_terms: D000367:Age Factors; D000907:Antibodies, Bacterial / Q000097:blood*; D000918:Antibody Specificity; D001770:Blood Bactericidal Activity; D005260:Female; D005312:Fetal Blood / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008585:Meningitis, Meningococcal / Q000276:immunology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000008:administration & dosage; D038542:Neisseria meningitidis, Serogroup C / Q000276:immunology* / Q000472:pathogenicity; D009426:Netherlands; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage; D012307:Risk Factors
chemical_list: D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial
references.citation: Euro Surveill. 2006 Mar 02;11(3):E060302.4
references.pmid: 16804223
references.citation: Clin Vaccine Immunol. 2009 Mar;16(3):433-6
references.pmid: 19129470
references.citation: Clin Infect Dis. 2009 Jul 1;49(1):58-64
references.pmid: 19480581
references.citation: Vaccine. 2007 Oct 10;25(41):7233-7
references.pmid: 17707957
references.citation: Pediatr Infect Dis J. 2005 Feb;24(2):128-31
references.pmid: 15702040
references.citation: Vaccine. 2003 Mar 7;21(11-12):1094-8
references.pmid: 12559785
references.citation: Clin Vaccine Immunol. 2008 Nov;15(11):1694-8
references.pmid: 18827191
references.citation: Vaccine. 2009 May 26;27(25-26):3435-8
references.pmid: 19200821
references.citation: Pediatr Infect Dis J. 2006 Jan;25(1):79-80
references.pmid: 16395110
references.citation: Arch Dis Child Fetal Neonatal Ed. 1996 Jan;74(1):F43-6
references.pmid: 8653435
references.citation: Vaccine. 2006 Apr 24;24(17):3500-4
references.pmid: 16517032
references.citation: Vaccine. 2001 Oct 15;20 Suppl 1:S58-67
references.pmid: 11587814
references.citation: Clin Vaccine Immunol. 2009 Feb;16(2):194-9
references.pmid: 19091990
references.citation: Euro Surveill. 2006 Sep 07;11(9):E060907.4
references.pmid: 17075143
references.citation: J Infect Dis. 2008 Mar 1;197(5):737-43
references.pmid: 18271745
references.citation: Clin Diagn Lab Immunol. 1997 Mar;4(2):156-67
references.pmid: 9067649
references.citation: Pediatr Infect Dis J. 2002 Aug;21(8):747-53
references.pmid: 12192163